Skip to main content

Table 2 Immunosuppressive regimen according to follow-up time in kidney transplant patients, (n = 450)

From: Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis

 

3 months N (%)

6 months N (%)

12 months N (%)

18 months N (%)

TAC/MPA/MP

212 (47.1)

217 (48.2)

215 (47.8)

210 (46.7)

CsA/MPA/MP

145 (32.2)

144 (32.0)

131 (29.1)

114 (25.3)

TAC/mTORi/MP

72 (16)

60 (13.3)

53 (11.8)

50 (11.1)

CsA/mTORi/MP

1 (0.2)

1 (0.2)

1 (0,2)

0 (0)

MPA/mTORi/MP

16 (3.6)

15 (3.3)

24 (5,3)

24 (5,3)

Double immunosuppressive regimen

2 (0.4)

3 (0.7)

15 (3,3)

36 (8.0)

None/unknown

2 (0.4)

10 (2.2)

11 (2.4)

16 (3.6)

  1. TAC: tacrolimus; MPA: mycophenolatemofetil or mycophenolate sodium; MP: methylprednisolone; CsA: cyclosporine; mTORi: rapammune or everolimus